World Vaccine Congress: A lymph node targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2

The SARS-CoV-2 pandemic’s public health, economic, and social impacts mandate urgent development of effective vaccines to contain or eradicate infection. To that end, we evaluated a novel amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid-modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor binding domain (Spike RBD) protein for immunization (ELI 005). AMP immunogens are efficiently delivered to lymph nodes, where innate and adaptive immune responses are generated.